Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in FGFR-altered Solid Tumors (AcSé PEMI)
NCT06653777Phase 2Recruiting
- Sponsor
- Unicancer
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of pemigatinib in solid tumor, sponsored by Unicancer. Started Mar 2025; status: recruiting.
02
Drugs
pemigatinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06653777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653777.